<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695810</url>
  </required_header>
  <id_info>
    <org_study_id>2015-001552-30</org_study_id>
    <nct_id>NCT02695810</nct_id>
  </id_info>
  <brief_title>The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes</brief_title>
  <official_title>Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordic Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to compare the short-term (3 months) effectiveness of three
      glucose-lowering interventions (dapagliflozin, metformin and physical activity) on glucose
      variability, body composition, and cardiometabolic risk factors in overweight or obese
      individuals with pre-diabetes (HbA1c 5.7-6.4% / 39-47 mmol/mol).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different medical therapies and lifestyle modification for the prevention of type 2 diabetes
      have yet to be compared head-to-head in individuals with pre-diabetes. This research project
      will compare different glucose-lowering interventions in overweight and obese individuals
      with HbA1c levels in the pre-diabetic range.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean amplitude of glycaemic excursions (MAGE) as assessed by continuous glucose monitoring</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-day glycaemic variability as assessed by continuous overall net glycaemic action (CONGA)</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily time spent above different glucose concentrations ( e.g. &gt;6.1 mmol/L, &gt;7.0 mmol/L, &gt;7.8 mmol/L, and &gt;11.1 mmol/L)</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations during OGTT</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion as assessed by the insulinogenic index</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity as assessed by the insulin sensitivity index</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kg)</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat (%) as assessed by DEXA scan</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory fitness as assessed by maximal oxygen uptake (VO2 max)</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory exchange ratio (RER) as assessed by indirect calorimetry</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal metabolic rate (BMR) as assessed by indirect calorimetry</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent sedentary and in moderate-to-vigorous physical activity intensity as assessed by accelerometer</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lipids</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of self-reported adverse events and side effects</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rated health and quality of life as assessed by questionnaire</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep habits as assessed by questionnaire</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake as assessed by a food diary</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the different interventions as assessed by number of tablets returned or number of training passes completed</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responsiveness to interventions in individuals with different glucose tolerance status (impaired fasting glycaemia vs. impaired glucose tolerance)</measure>
    <time_frame>Change from baseline to 13 weeks and 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prediabetic State</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin, 10 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin, 2 x 850 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exercise, interval training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10 mg per day as monotherapy for 13 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga, AstraZeneca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>2 x 850 mg per day as monotherapy for 13 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Aurobindo, Orion Pharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Interval training, 5 times per week, 30 min per session</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c: from ≥5.7% (39 mmol/mol) to ≤6.4% (47 mmol/mol)

          -  Age: from ≥30 to ≤70 years of age

          -  BMI ≥25 kg/m2

        Exclusion Criteria:

          -  Uncontrolled medical issues including but not limited to cardiovascular pulmonary,
             rheumatologic, hematologic, oncologic, infectious, gastrointestinal or psychiatric
             disease; diabetes or other endocrine disease; immunosuppression;

          -  Current treatment with hormones which affect glucose metabolism;

          -  Current treatment with loop diuretics or thiazolidinediones;

          -  Current treatment with beta blockers or peroral steroids;

          -  Bariatric surgery within the past 2 years;

          -  Impaired renal function defined as an estimated GFR&lt;60 ml/min/1.73m2;

          -  Neurogenic bladder disorders;

          -  Alcohol/drug abuse or in treatment with disulfiram (Antabus) at time of inclusion;

          -  Pregnant or lactating women;

          -  Fertile women not using birth control agents including oral contraceptives, gestagen
             injection, subdermal implants, hormonal vaginal ring, transdermal application, or
             intra-uterine devices;

          -  Allergic to one or more of the medications used in the study;

          -  Concomitant participation in other intervention study;

          -  Unable to understand the informed consent and the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marit E Jørgensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristine Færch, PhD</last_name>
    <phone>+4530791461</phone>
    <email>krif@steno.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanan Amadid, MD</last_name>
    <phone>+4530756704</phone>
    <email>hamd@steno.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Steno Diabetes Center A/S</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Færch, PhD</last_name>
      <phone>+4530791461</phone>
      <email>krif@steno.dk</email>
    </contact>
    <contact_backup>
      <last_name>Marit E Jørgensen, PhD</last_name>
      <phone>+4530756008</phone>
      <email>maej@steno.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Hanan Amadid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lea B Nielsen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://steno.dk/</url>
    <description>Steno Diabetes Center</description>
  </link>
  <reference>
    <citation>Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications. 2014 Mar-Apr;28(2):226-33. doi: 10.1016/j.jdiacomp.2013.10.008. Epub 2013 Oct 28. Review.</citation>
    <PMID>24342268</PMID>
  </reference>
  <reference>
    <citation>Faerch K, Hulmán A, Solomon TP. Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. Curr Diabetes Rev. 2016;12(1):30-41. Review.</citation>
    <PMID>25877695</PMID>
  </reference>
  <reference>
    <citation>Færch K, Vistisen D, Johansen NB, Jørgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep. 2014 Jun;14(6):493. doi: 10.1007/s11892-014-0493-1. Review.</citation>
    <PMID>24743942</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center</investigator_affiliation>
    <investigator_full_name>Kristine Færch</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

